A porphycene-gentamicin conjugate for enhanced photodynamic inactivation of bacteria

Bioorg Chem. 2020 Apr:97:103661. doi: 10.1016/j.bioorg.2020.103661. Epub 2020 Feb 11.

Abstract

A novel photoantimicrobial agent, namely 2-aminothiazolo[4,5-c]-2,7,12,17-tetrakis(methoxyethyl)porphycene (ATAZTMPo-gentamicin) conjugate, has been prepared by a click reaction between the red-light absorbing 9-isothiocyanate-2,7,12,17-tetrakis(methoxyethyl)porphycene (9-ITMPo) and the antibiotic gentamicin. The conjugate exhibits submicromolar activity in vitro against both Gram-positive and Gram-negative bacteria (Staphylococcus aureus and Escherichia coli, respectively) upon exposure to red light and is devoid of any cytotoxicity in the dark. The conjugate outperforms the two components delivered separately, which may be used to enhance the therapeutic index of gentamicin, broaden the spectrum of pathogens against which it is effective and reduce its side effects. Additionally, we report a novel straightforward synthesis of 2,7,12,17-tetrakis(methoxyethyl) porphycene (TMPo) that decreases the number of steps from nine to six.

Keywords: Amphiphilicity; Antimicrobial resistance; Photodynamic therapy; Photosensitizer conjugates; Porphycene; Singlet oxygen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemistry*
  • Anti-Bacterial Agents / pharmacology*
  • Escherichia coli / drug effects
  • Escherichia coli Infections / drug therapy
  • Gentamicins / chemistry*
  • Gentamicins / pharmacology*
  • Humans
  • Photochemotherapy
  • Photosensitizing Agents / chemistry
  • Photosensitizing Agents / pharmacology
  • Porphyrins / chemistry*
  • Porphyrins / pharmacology*
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus / drug effects

Substances

  • Anti-Bacterial Agents
  • Gentamicins
  • Photosensitizing Agents
  • Porphyrins
  • porphycene